Sept 26 (Reuters) – Italy’s Alfasigma S.p.A said on Tuesday it had agreed to buy U.S. drugmaker Intercept Pharmaceuticals ICPT.O for $794 million to expand its presence in the United States.

Alfasigma will pay $19 per Intercept share, which represents a premium of 82% to its last closing price.

(Reporting by Manas Mishra in Bengaluru; Editing by Shilpi Majumdar)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.